Sanofi and Regeneron Extend the Type-2 Alliance

Company Sanofi / Regeneron Event Type Deal / Alliance Expansion Modality Monoclonal and Bispecific Antibodies Asset REGN20423 (IL-13) and Three Preclinical Antibodies (IL-4×IL-13, IL-4, IL-4Rα) Target IL-13 / IL-4 / IL-4Rα Disease Area Type-2 Inflammatory Disease (Atopic Dermatitis and Others) Summary Sanofi and Regeneron expanded…